Sara Elsafy

Sara Elsafy

Auto-generated profile, based on publicly available information

Sara Elsafy

Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
ASAya Sebak
Aya Sebak
BEBasma El-Shenawy
Basma El-Shenawy
SESara El-Safy
Sara El-Safy
Mohamed El-ShazlyMohamed El-Shazly
Mohamed El-Shazly
Nanomedicine is revolutionizing the treatment of cancer and has achieved unprecedented outcomes over the past decades. The accumulation of Nanoparticles (NPs) in different tumors relies mainly on the Enhanced Permeability and Retention (EPR) effect benefiting from the wide fenestrae of the tumor vasculature and the lack of lymphatic drainage. However, the EPR effect is recognized as a heterogeneous phenomenon resulting in heterogeneous outcomes of clinical trials. Extensive efforts are exerted to enhance the outcomes of nanomedicine in a larger cohort of patients by employing active targeting strategies. However, actively targeted NPs accumulate in tumors by the EPR effect and hence fail to achieve convincing therapeutic outcomes. These obstacles are gradually being removed by improving the understanding of the Tumor Microenvironment (TME) and the mechanistic interaction of the NPs with its different components. In this review, we provide detailed insights into the past concerns of drug targeting, the current trends of TME reengineering, and the future implications for overcoming past hurdles. Strategies explored in this regard included the use of companion diagnostics and the modulation of the protein corona associated with the systemic administration of NPs and their interaction with biological macromolecules.

14 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SESara Elsafy
Sara Elsafy
SKShiva Khorshid
Shiva Khorshid
ANAlessia Nucci
Alessia Nucci
FLFederica De Lorenzi
Federica De Lorenzi
AMAlessandro Motta
Alessandro Motta
ASAlexandros Marios Sofias
Alexandros Marios Sofias
Nanoparticle design principles contribute to desirable in vivo performance, including prolonged circulation, desirable biodistribution profiles, and tuned interactions with the immune system. The importance of these variables, although well-established in solid tumors, remains elusive in the context of hematological malignancies. Here, we investigated the influence of liposome size on biodistribution and cellular uptake within hematopoietic compartments - bone marrow (BM) and spleen - in JAK2V617F myeloproliferative neoplasms (MPN). A milli-fluidic manufacturing platform combined with a Design-of-Experiments (DoE) approach was used to generate small, medium, and large liposomes. Liposome uptake was assessed ex vivo using blood samples from healthy donors and MPN patients, followed by in vivo biodistribution studies in a transgenic JAK2V617F MPN mouse model. Organ-level accumulation was quantified using hybrid fluorescence / computed tomography (FLT/CT) imaging, while cellular uptake was evaluated via flow cytometry. Whole-body imaging revealed that increasing liposome size enhanced delivery to both the spleen and BM, with larger liposomes exhibiting the highest accumulation in both organs. Cellular analysis corroborated the in vivo observations, demonstrating that large liposomes are taken up to a greater extent by monocytes and granulocytes, in both spleen and BM. At late time-points post-injection, the liposomal accumulation was twice as high in the BM in comparison to the spleen and peripheral blood, highlighting the progressively elevated accumulation and retention in the BM, as opposed to the elimination phase nanoparticles undergo in clearance organs and circulation at these time-points. Of note, among BM mature myeloid cells, neutrophils were associated with a higher nanoparticle uptake than monocytes, highlighting their capability to phagocytose material in circulation and hitchhike it to malignant or inflamed regions. These findings demonstrate that continuous flow manufacturing procedures can swiftly produce nanoparticles with desirable characteristics that are essential for tuning the biodistribution towards hematopoietic organs and myeloid immune cells. By providing mechanistic insights into nanoparticle behavior within hematopoietic compartments, this work advances our understanding of nanomedicine in vivo performance and highlights particle size as a critical quality attribute that can be optimized and controlled to improve targeted delivery to myeloid cells in the treatment of hematological malignancies.

22 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SESara Elsafy
Sara Elsafy
MDMartin Dulle
Martin Dulle
SSSaba Shahzad
Saba Shahzad
THThomas Hammoor
Thomas Hammoor
MWMarek Weiler
Marek Weiler
ASAlexandros Marios Sofias
Alexandros Marios Sofias
Lipid nanoparticles (LNP) are widely used for nucleic acid delivery, with current optimization efforts mainly focusing on refining formulation features, enabling extrahepatic targeting, and improving therapeutic efficacy. Particle shape and internal architecture are variables often overlooked in LNP design, although they critically influence particle stability, biodistribution, cellular uptake, and transfection. Here, we investigate how formulation and process parameters impact LNP shape, morphology, and internal structure, and how these structural features, in turn, influence mRNA loading, cell uptake, and expression. We demonstrate that modulation of lipid composition by increasing DSPC content drives a transition from compact spherical to vesicular non-spherical morphologies, with altered RNA loading at the single-particle level. While non-spherical LNP exhibited higher cellular uptake than spherical LNP, it was identified that this increase was relatively modest compared with the substantially higher and sustained protein expression for non-spherical structures. This suggests that increased uptake alone cannot explain the enhanced transfection performance. The trend was conserved across LNP formulations comprising clinically relevant ionizable lipids SM-102, ALC-0315 and DLin-MC3-DMA. Taken together, these findings establish LNP shape and internal morphology as functionally relevant design variables that should be considered in the design of next-generation LNP with improved mRNA delivery and expression. Graphical